WO1999053936A1 - Hypoglycemic agents - Google Patents

Hypoglycemic agents Download PDF

Info

Publication number
WO1999053936A1
WO1999053936A1 PCT/JP1999/002031 JP9902031W WO9953936A1 WO 1999053936 A1 WO1999053936 A1 WO 1999053936A1 JP 9902031 W JP9902031 W JP 9902031W WO 9953936 A1 WO9953936 A1 WO 9953936A1
Authority
WO
WIPO (PCT)
Prior art keywords
hair
extract
corn
blood sugar
pick
Prior art date
Application number
PCT/JP1999/002031
Other languages
French (fr)
Japanese (ja)
Inventor
Zai-Si Ji
Hiroyuki Itoh
Xiao Lin Wang
Jian Sheng Tao
Original Assignee
Shanghai Meiji Health Pharmaceutical Corp., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Meiji Health Pharmaceutical Corp., Ltd. filed Critical Shanghai Meiji Health Pharmaceutical Corp., Ltd.
Priority to AU33444/99A priority Critical patent/AU3344499A/en
Publication of WO1999053936A1 publication Critical patent/WO1999053936A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to a hypoglycemic agent containing an extract of corn hair as an active ingredient, and a food or drink containing the extract.
  • Diabetes is a disease that causes a chronic systemic metabolic disorder and exhibits a chronic hyperglycemic state.
  • Many factors are thought to be involved in the pathogenesis, such as abnormalities in many environmental factors, insulin receptor genes, or sugar transporter genes.
  • the primary regulator of blood sugar is insulin, which is synthesized and secreted by ⁇ cells, and hyperglycemia is caused by a lack of insulin or an excess of factors that antagonize its effects.
  • Insulin deficiency causes abnormal metabolism of sugars, proteins, and fats, resulting in various complications such as acidosis, abnormalities in the kidney and retina capillaries, peripheral neuropathy, and accelerated development of atherosclerosis.
  • the goal of diabetes treatment is to eliminate insulin deficiency in all tissues of the whole body, to normalize and maintain metabolism, and to prevent and control these acute and chronic complications. is there.
  • Dietary therapy (restricted calories) and exercise therapy are commonly used to treat diabetes and impaired glucose tolerance, and when these therapies do not control blood sugar well, Drug therapy is given. Dietary or exercise therapy is a major mental and physical stress for patients. In pharmacotherapy, it is required that drugs such as oral hypoglycemic agents used have no side effects and can be taken continuously and safely over a long period of time.
  • an object of the present invention is to provide a novel crude drug extract having an excellent blood glucose lowering action. Disclosure of the invention
  • the present invention provides a hypoglycemic agent comprising an extract of corn pick-up hair as an active ingredient.
  • the present invention also provides a food or drink having a blood sugar lowering action or a blood sugar rise suppressing action, which contains an extract of corn pick-up hair.
  • the present invention provides use of a corn D. kompa hair extract for the production of a food or drink having a blood sugar lowering action or a blood sugar rise suppressing action. Furthermore, the present invention provides a method for treating diabetes, which comprises administering an extract of corn pick-up hair.
  • FIG. 1 is a diagram showing a gel filtration chromatogram of a corn pick-up hair extract.
  • FIG. 2 is a graph showing the blood glucose lowering effect of a corn pick-up hair extract in an STZ-induced diabetes model rat.
  • Nanba hair refers to the style and stigma (Corn silk; also called Nanban hair) of fresh flowers of corn Zea mays of the Gramineae family.
  • the production areas are widely distributed in China, Japan, Korea, and so on.
  • Pharmacological actions such as diuresis, blood pressure lowering, and bile secretion promoting action have been reported [Tsuneo Namba: Encyclopedia of Japanese and Chinese Medicine [I] : 131, 1994, Nursing Co., Ltd.].
  • Nampa hair used in the present invention may be derived from corn of all varieties cultivated in various parts of the world, but is preferably derived from maize cultivated from Shandong province, China, cultivar ye simple 12 or ye simple 14 corn. Dried number hair.
  • the hair extract of Nampa can be obtained by using a general method used for extracting an active ingredient from a herbal medicine.
  • the hair of a pick-up pick up the hair of a pick-up and dry it.
  • it is extracted with a solvent.
  • the extraction is performed using water, aqueous ethanol, or weakly acidic water, which is about 10 to 30 times that of the pulverized or pulverized sample.
  • the extraction temperature is from room temperature to the boiling point of the extraction solvent, preferably extraction with hot water.
  • the extraction time is 30 minutes to several hours under hot water with stirring. Obtained Can the extracted liquid be used as it is as an extract of the hair of the picked-up hair of the present invention?-In order to further concentrate the active ingredients of the extracted liquid, the extract is separated into solid and liquid by filtration and centrifugation.
  • the liquid phase may be concentrated under reduced pressure (95 ° C or less).
  • the concentrated liquid may be further dried by a spray drying method, a reduced pressure drying method, or a freeze drying method to obtain a powder.
  • the extract may be further subjected to chromatography or the like.
  • the hair extract of Nampa thus obtained alone has a blood glucose lowering action, but has another blood glucose lowering action.
  • Synergistic or additive effects can be expected when used with food extract components.
  • a hot water extract of cultured mycelium of Cordyceps s inens is (Berkeley) Saccard has various pharmacological effects such as cardiotonic, hypotensive, antitussive, anti-fatigue and hypoglycemic effects.
  • the hair extract of Nampa of the present invention is used as a blood glucose lowering agent or a blood glucose elevation inhibitor in pharmaceuticals
  • the extract is used as a dry solid content per day for adults. It can be administered orally in the range of l-20g / kg.
  • Dried corn wool (Yamada No. 12 from Shandong, China) was immersed in about 15 times the volume of water for 30 minutes, and then boiled for 1 hour to extract the active ingredients. About 8 times the amount of water was added to the extraction residue, and the mixture was boiled for 1 hour. The extracts were combined and filtered through a 100 mesh sieve. The filtrate was concentrated under reduced pressure to a specific gravity of 1.08. The concentrate is centrifuged
  • Figure 1 shows a gel filtration chromatogram of the extract (3.33 g / 100 mL of dry solids).
  • a 7-week-old male SD (Sprague-Dawley) rat was preliminarily reared for one week, and then 50 mg / 2m / kg of streptozotocin (STZ) was administered from the tail vein of each rat.
  • STZ streptozotocin
  • the blood glucose level of each rat was measured.
  • the obtained STZ-induced diabetes mellitus rats were divided into an extract administration group (6 animals) and a control group (6 animals) so that the average blood glucose level was almost the same. Three rats were used as a normal group (no administration).
  • Example 2 The extract of corn pick-up hair obtained in Example 1 was orally administered (dry solids: 4.07 g / kg / day) from the third day after STZ administration to the extract-administered group for 7 consecutive days. .
  • distilled water was orally administered.
  • Figure 2 shows the daily fluctuation of blood glucose in each group Shown in The following is clear from FIG.
  • the blood glucose level in the normal group remained almost constant at about 110 mg / dL during the test period.c
  • the STZ-induced diabetic group showed a level of 557 mg / dL on the first day of administration.
  • the blood glucose level was higher than that of, and thereafter, a persistently high blood glucose level of around 530 mg / dL was shown.
  • the blood sugar lowering effect of an extract of corn hair was revealed.
  • the extract can be used as a preventive or therapeutic agent for diabetes, or as a preventive agent for arteriosclerotic vascular disorders caused by impaired glucose tolerance.
  • by incorporating the extract into foods and drinks and ingesting the extract it is possible to expect continuous improvement or prevention of diabetes in daily eating habits.

Abstract

Hypoglycemic agents containing as the active ingredient corn silk extract; and drinks and foods containing the same.

Description

明 細 書 血糖値降下剤 技術分野  Description Blood glucose lowering agent Technical field
本発明は、 トウモロコシのナン の毛の抽出物を有効成分とする血糖値降下剤 及び該抽出物を含有する飲食品に関する。 背景技術  The present invention relates to a hypoglycemic agent containing an extract of corn hair as an active ingredient, and a food or drink containing the extract. Background art
近年、 糖尿病の発症頻度は、 高血圧、 癌とともに増加の傾向にある。 その背景 には、 食生活の豊かさによるカロリーの過剰摂取、 労働 '運動不足、 或いは精神 的ストレス等の他に、 加齢に伴う耐糖能低下を基にした老年糖尿病患者の激増が あ o  In recent years, the incidence of diabetes has been increasing with hypertension and cancer. Behind this are the excessive intake of calories due to the abundance of dietary habits, lack of work and exercise, and mental stress, as well as the burgeoning number of elderly diabetics based on aging-related decline in glucose tolerance.
糖尿病は、 慢性の全身性代謝障害を引き起こす疾患であって、 慢性の高血糖状 態を呈する。 その発症には、 多くの環境因子やインスリ ン受容体遺伝子、 或いは 糖輸送担体遺伝子の異常など、 多くの因子が関与していると考えられている。 血 糖の主な調節因子は、 脬 細胞で合成 '分泌されるインスリンで、 高血糖は、 ィ ンスリ ンの欠乏又はその作用に拮抗する因子の過剰で起こる。 インスリンの欠乏 で、 糖、 タンパク、 脂肪の代謝異常が起こり、 その結果、 アシドーシス、 腎及び 網膜の毛細血管異常、 末梢神経障害、 動脈硬化の進展促進などのさまざまな合併 症が引き起こされる。  Diabetes is a disease that causes a chronic systemic metabolic disorder and exhibits a chronic hyperglycemic state. Many factors are thought to be involved in the pathogenesis, such as abnormalities in many environmental factors, insulin receptor genes, or sugar transporter genes. The primary regulator of blood sugar is insulin, which is synthesized and secreted by 脬 cells, and hyperglycemia is caused by a lack of insulin or an excess of factors that antagonize its effects. Insulin deficiency causes abnormal metabolism of sugars, proteins, and fats, resulting in various complications such as acidosis, abnormalities in the kidney and retina capillaries, peripheral neuropathy, and accelerated development of atherosclerosis.
糖尿病の治療の目標は、 全身のあらゆる組織のインスリン作用不足を解消して、 代謝の正常化を図り、 これを維持することで、 これら急性及び慢性の合併症の予 防 -抑制を行うことである。  The goal of diabetes treatment is to eliminate insulin deficiency in all tissues of the whole body, to normalize and maintain metabolism, and to prevent and control these acute and chronic complications. is there.
糖尿病や耐糖能障害の治療には、 食餌療法 （カロリー制限） や運動療法が一般 に行われており、 これらの療法で、 血糖値がうまくコントロールできない場合に、 薬物療法が行われる。 食餌療法或いは運動療法は、 患者にとって、 大きな精神 的 ·肉体的ストレスとなっている。 また、 薬物療法においては、 使用される経口 血糖値降下剤等の薬剤は、 副作用がなく、 長期間にわたって継続的に安心して摂 取できる薬剤であることが要求されている。 Dietary therapy (restricted calories) and exercise therapy are commonly used to treat diabetes and impaired glucose tolerance, and when these therapies do not control blood sugar well, Drug therapy is given. Dietary or exercise therapy is a major mental and physical stress for patients. In pharmacotherapy, it is required that drugs such as oral hypoglycemic agents used have no side effects and can be taken continuously and safely over a long period of time.
このような状況のなかで、 ヒトが通常食している食品の中で、 血糖値降下作用 をもつ成分の探索が行われ、 その結果、 血糖値降下作用を有するとされるさまざ まな食品成分が提案されている。 例えば、 トウモロコシ外皮より得られたへミセ ルロースの部分分解物を有効成分とする耐糖能障害改善剤が提案されている （特 開平 7- 324036号） 。 しかしながら、 トウモロコシのナンパの毛の抽出物が血糖値 降下作用を有するとした先行技術は見当らない。  In such a situation, among the foods that humans normally eat, a search for components having a hypoglycemic effect is conducted, and as a result, various food components that are considered to have a hypoglycemic effect are found. Proposed. For example, there has been proposed a glucose tolerance disorder improving agent containing a partially degraded hemicellulose obtained from corn husk as an active ingredient (Japanese Patent Publication No. Hei 7-324036). However, there is no prior art that corn pick-up hair extract has a hypoglycemic effect.
したがって、 本発明は、 優れた血糖値降下作用を有する新規な生薬抽出物を提 供することを課題とする。 発明の開示  Therefore, an object of the present invention is to provide a novel crude drug extract having an excellent blood glucose lowering action. Disclosure of the invention
本発明者らは、 上記課題を解決するために鋭意検討した結果、 トウモロコシの ナンパの毛の抽出物が、 優れた血糖値降下作用を有することを見出し、 本発明を 元成した。  Means for Solving the Problems The present inventors have conducted intensive studies in order to solve the above problems, and as a result, have found that an extract of corn pick-up hair has an excellent blood sugar level lowering action, and have formed the present invention.
すなわち、 本発明は、 トウモロコシのナンパの毛の抽出物を有効成分とする血 糖値降下剤を提供するものである。  That is, the present invention provides a hypoglycemic agent comprising an extract of corn pick-up hair as an active ingredient.
また、 本発明はトウモロコシのナンパの毛の抽出物を含有する血糖値降下作用 又は血糖値上昇抑制作用を有する飲食品を提供するものである。  The present invention also provides a food or drink having a blood sugar lowering action or a blood sugar rise suppressing action, which contains an extract of corn pick-up hair.
さらに本発明は、 血糖値降下作用又は血糖値上昇抑制作用を有する飲食品の製 造のためのトウモ Dコシのナンパの毛の抽出物の使用を提供するものである。 さらに本発明は、 トウモロコシのナンパの毛の抽出物を投与することを特徴と する糖尿病の処置方法を提供するものである。 図面の簡単な説明 Further, the present invention provides use of a corn D. kompa hair extract for the production of a food or drink having a blood sugar lowering action or a blood sugar rise suppressing action. Furthermore, the present invention provides a method for treating diabetes, which comprises administering an extract of corn pick-up hair. BRIEF DESCRIPTION OF THE FIGURES
図 1は、 トウモロコシのナンパの毛の抽出物のゲル濾過クロマトグラムを示す 図である。  FIG. 1 is a diagram showing a gel filtration chromatogram of a corn pick-up hair extract.
カラム： Superdex 30 prep grade  Column: Superdex 30 prep grade
カラムサイズ： 16■ ID ネ 60cm し  Column size: 16 ■ ID 60cm
流速： 1. OmL/min  Flow rate: 1. OmL / min
注入量： 50 L  Injection volume: 50 L
溶出液： lOmM HEPES-NaOH (pH7. 4)/1 M NaC ^  Eluent: lOmM HEPES-NaOH (pH 7.4) / 1 M NaC ^
図 2は、 STZ誘発糖尿病モデルラッ トにおける、 トウモロコシのナンパの毛の 抽出物の血糖値降下作用を示す図である。 発明を実施するための最良の形態  FIG. 2 is a graph showing the blood glucose lowering effect of a corn pick-up hair extract in an STZ-induced diabetes model rat. BEST MODE FOR CARRYING OUT THE INVENTION
ナンバの毛とは、 イネ科 （Gramineae)のトウモロコシ Zea mays しの新鮮花の 花柱と柱頭 （Corn s i lk；南蛮毛ともいう） をいう。 産地は、 中国、 日本、 韓国 など広く分布している。 薬理作用として、 利尿、 血圧降下、 胆汁分泌促進作用等 が報告されている 〔難波恒雄：和漢薬百科図鑑 [ I ] : 1 3 1 , 平成 6年， (株） 保育社〕 。 Nanba hair refers to the style and stigma (Corn silk; also called Nanban hair) of fresh flowers of corn Zea mays of the Gramineae family. The production areas are widely distributed in China, Japan, Korea, and so on. Pharmacological actions such as diuresis, blood pressure lowering, and bile secretion promoting action have been reported [Tsuneo Namba: Encyclopedia of Japanese and Chinese Medicine [I] : 131, 1994, Nursing Co., Ltd.].
本発明において用いられるナンパの毛は、 世界各地で栽培される全ての品種の トウモロコシ由来であってもよいが、 好ましくは、 中国山東省産の品種掖単 12号 または掖単 14号トウモロコシ由来のナンバの毛の乾燥品である。  Nampa hair used in the present invention may be derived from corn of all varieties cultivated in various parts of the world, but is preferably derived from maize cultivated from Shandong Province, China, cultivar ye simple 12 or ye simple 14 corn. Dried number hair.
ナンパの毛の抽出物は、 植物生薬からの有効成分の抽出に用いられている一般 的な方法を用いて得ることができる。  The hair extract of Nampa can be obtained by using a general method used for extracting an active ingredient from a herbal medicine.
例えば、 ナンパの毛を採取し、 乾燥する。 次に溶媒で抽出する。 抽出は、 紬切 または粉砕した試料の約 1 0〜3 0倍の水、 水性エタノール、 或いは、 弱酸性の 水等を用いて行う。 抽出温度は、 常温〜抽出溶媒の沸点温度、 好ましくは熱水に よる抽出である。 抽出時間は、 熱水の場合 3 0分〜数時間攪拌下に行う。 得られ た抽出液は、 そのまま本発明のナンパの毛の抽出物として用いることができるか- 抽出液の有効成分をさらに濃縮するために、 抽出液は、 濾過、 遠心分離により、 固、 液を分離し、 液相部分を減圧下 （95°C以下） で濃縮してもよい。 濃縮液は、 さらに、 噴霧乾燥法、 減圧乾燥法、 或いは、 凍結乾燥法により乾燥して、 粉末と してもよい。 また、 必要に応じて、 本抽出液をクロマトグラフィー等によりさら このようにして得られたナンパの毛の抽出物は、 単独で、 血糖値降下作用 を有するが、 他の血糖値降下作用を有する食品抽出成分と一緒に用いることに より、 相乗的、 或いは相加的効果が期待できる。 例えば、 冬虫夏草 [Cordyceps s inens i s (Berkeley) Saccard] の培養菌糸体の熱水抽出物は、 強心作用、 降圧 作用、 鎮咳作用、 抗疲労作用及び血糖値降下作用等のさまざまな薬理効果を有す る （W096/00580公開公報） ので、 該抽出物と共に、 ナンバの毛の抽出物を、 医薬 品として用いることにより、 或いは飲食品に添加することにより、 相乗的、 或い は相加的な血糖値降下作用を含めたさまざまな薬効が期待できると考えられる。 ナンパの毛の抽出物を血糖値降下、 或いは血糖値上昇抑制のための医薬品とし て用いる場合は、 適当な賦形剤 （乳糖、 コーンスターチ、 結晶セルロース等） を 加えて混合し、 様々な剤型 （錠剤、 カプセル剤、 散財、 細粒剤、 顆粒剤等） にし て、 経口投与することができる。 また、 ナンパの毛の抽出物を、 飲食品に少量添 加することにより、 飲食品の風味をそこなうことなく、 日常の食生活のなかで糖 尿病の改善或いは予防効果が期待できる。 For example, pick up the hair of a pick-up and dry it. Next, it is extracted with a solvent. The extraction is performed using water, aqueous ethanol, or weakly acidic water, which is about 10 to 30 times that of the pulverized or pulverized sample. The extraction temperature is from room temperature to the boiling point of the extraction solvent, preferably extraction with hot water. The extraction time is 30 minutes to several hours under hot water with stirring. Obtained Can the extracted liquid be used as it is as an extract of the hair of the picked-up hair of the present invention?-In order to further concentrate the active ingredients of the extracted liquid, the extract is separated into solid and liquid by filtration and centrifugation. The liquid phase may be concentrated under reduced pressure (95 ° C or less). The concentrated liquid may be further dried by a spray drying method, a reduced pressure drying method, or a freeze drying method to obtain a powder. In addition, if necessary, the extract may be further subjected to chromatography or the like. The hair extract of Nampa thus obtained alone has a blood glucose lowering action, but has another blood glucose lowering action. Synergistic or additive effects can be expected when used with food extract components. For example, a hot water extract of cultured mycelium of Cordyceps s inens is (Berkeley) Saccard has various pharmacological effects such as cardiotonic, hypotensive, antitussive, anti-fatigue and hypoglycemic effects. (W096 / 00580 publication), so that the extract of the hair of Namba is used together with the extract as a medicine or added to foods and drinks to produce synergistic or additive blood glucose. It is expected that various medicinal effects including a value-lowering effect can be expected. When using Nampa hair extract as a drug for lowering or lowering blood sugar levels, add appropriate excipients (lactose, corn starch, crystalline cellulose, etc.) and mix to obtain various dosage forms. (Tablets, capsules, splinters, fine granules, granules, etc.) and can be administered orally. In addition, by adding a small amount of the picked-up hair extract to foods and drinks, it is possible to expect the improvement or prevention of diabetes mellitus in daily eating habits without impairing the flavor of the foods and drinks.
本発明のナンパの毛の抽出物を血糖値降下剤、 或いは血糖値上昇抑制剤として 医薬品に用いる場合は、 該抽出物を、 成人に対して、 1 日あたり、 乾燥固形分と して 0. l〜20g/kgの範囲で、 経口投与することができる。 実施例  In the case where the hair extract of Nampa of the present invention is used as a blood glucose lowering agent or a blood glucose elevation inhibitor in pharmaceuticals, the extract is used as a dry solid content per day for adults. It can be administered orally in the range of l-20g / kg. Example
以下、 本発明を実施例により、 具体的に説明するが、 本発明は、 これらの実施 例に限定されるものではない。 Hereinafter, the present invention will be described specifically with reference to examples. It is not limited to the example.
実施例 1 抽出物の製造 Example 1 Production of extract
トウモロコシのナンパの毛 （中国山東省産の掖単 1 2号） の乾燥品を約 15倍量 の水に 30分間浸漬した後、 1時間煮沸して有効成分を抽出した。 抽出残渣には、 約 8倍量の水を加え、 1時間煮沸した。 抽出液は一緒にし、 100メッシュの篩で 濾過した。 濾液は、 比重 1. 08となるまで減圧濃縮した。 濃縮液は、 遠心分離 Dried corn wool (Yamada No. 12 from Shandong, China) was immersed in about 15 times the volume of water for 30 minutes, and then boiled for 1 hour to extract the active ingredients. About 8 times the amount of water was added to the extraction residue, and the mixture was boiled for 1 hour. The extracts were combined and filtered through a 100 mesh sieve. The filtrate was concentrated under reduced pressure to a specific gravity of 1.08. The concentrate is centrifuged
(2000r. p. mで 20分） し、 その上清液は、 加熱殺菌し、 トウモロコシのナンパの 毛の熱水抽出物を得た。 図 1に該抽出物 （乾燥固形分 3. 33g/100mL) のゲル濾過 クロマトグラムを示す。 (2000 rpm for 20 minutes), and the supernatant was heat-sterilized to obtain a hot water extract of corn pick-up hair. Figure 1 shows a gel filtration chromatogram of the extract (3.33 g / 100 mL of dry solids).
実施例 2 抽出物を含有する飲食品の製造例 Example 2 Production Example of Food and Beverage Containing Extract
実施例 1で得たトウモロコシのナンパの毛の抽出物 65. 6kg、 冬虫夏草熱水 抽出物 （W096/00580参照） 3. 33kg (固形分濃度 50mg/mい 、 甘味料 5. 0kg、 クェン 酸 0. 5kg, リンゴ酸 0. 5kg及び香料 0. 1kgに水を加えて全量を 100kgとし撹拌溶解し た。 保存料 0. 07kgは、 アルコール 0. 5 1に溶解し添加した。 予備殺菌後、 ボトル に充塡、 90°Cの熱水に 2時間浸漬した。 その後 1晚自然放冷して本発明の抽出物 を含有する飲料製品を得た。  65.6 kg of corn pick-up hair extract obtained in Example 1, Cordyceps hot water extract (see W096 / 00580) 3.33 kg (solids concentration 50 mg / m, sweetener 5.0 kg, citric acid 0) 5 kg, 0.5 kg of malic acid and 0.1 kg of fragrance were mixed with water to make the total amount 100 kg, and dissolved by stirring, and 0.07 kg of preservative was dissolved in alcohol 0.51 and added. And immersed in hot water at 90 ° C. for 2 hours, and then allowed to cool naturally for 1 hour to obtain a beverage product containing the extract of the present invention.
実施例 3 血糖値降下試験 Example 3 Blood glucose lowering test
7週令の SD (Sprague-Dawl ey) 系雄性ラッ トを、 1週間予備飼育した後、 スト レプトゾトシン （s treptozotocin : STZ) 50mg/2mし/ kgを各ラッ トの尾静脈から投 与した。 STZ投与後 3日目に、 各ラッ 卜の血糖値を測定した。 得られた STZ誘発糖 尿病ラッ トについて、 血糖値の平均値がほぼ同じになるように、 抽出物投与群 ( 6匹） と対照群 （6匹） に群分けした。 正常群 （何も投与しない） として、 ラ ッ ト 3匹を用いた。  A 7-week-old male SD (Sprague-Dawley) rat was preliminarily reared for one week, and then 50 mg / 2m / kg of streptozotocin (STZ) was administered from the tail vein of each rat. On day 3 after STZ administration, the blood glucose level of each rat was measured. The obtained STZ-induced diabetes mellitus rats were divided into an extract administration group (6 animals) and a control group (6 animals) so that the average blood glucose level was almost the same. Three rats were used as a normal group (no administration).
実施例 1で得たトウモロコシのナンパの毛の抽出物を、 抽出物投与群に対し、 STZ投与後 3日目から連続 7日間経口投与 （乾燥固形分として 4. 07g/kg/日） し た。 対照群に対しては、 蒸留水を経口投与した。 各群の血糖値の日間変動を図 2 に示す。 図 2から、 以下のことが明らかである。 The extract of corn pick-up hair obtained in Example 1 was orally administered (dry solids: 4.07 g / kg / day) from the third day after STZ administration to the extract-administered group for 7 consecutive days. . For the control group, distilled water was orally administered. Figure 2 shows the daily fluctuation of blood glucose in each group Shown in The following is clear from FIG.
(1) 正常群の血糖値は、 試験期間中、 約 110mg/dLと、 ほぼ一定で推移を示した c これに対し、 STZ誘発糖尿病群は、 投与初日には、 557mg/dLと、 正常群に比較し て高い血糖値を示し、 その後は、 530mg/dL前後と持続的な高血糖値を示した。  (1) The blood glucose level in the normal group remained almost constant at about 110 mg / dL during the test period.c On the other hand, the STZ-induced diabetic group showed a level of 557 mg / dL on the first day of administration. The blood glucose level was higher than that of, and thereafter, a persistently high blood glucose level of around 530 mg / dL was shown.
(2) 該 STZ誘発糖尿病モデルラッ トを用いた血糖降下試験において、 抽出物投 与群では、 該抽出物投与 3日目に、 血糖値は、 370mg/dしと対照群に比較して、 著 明に低い値を示した。 その後も、 血糖値は、 ほぼ 400mg/dしと一定の低い値で推移 した。  (2) In a blood glucose lowering test using the STZ-induced diabetes model rat, in the extract-administered group, on the third day of the extract administration, the blood glucose level was 370 mg / d, which was significantly lower than that in the control group. The value was clearly lower. After that, the blood glucose level remained at a certain low value of almost 400 mg / d.
(3) 以上のことから、 トウモロコシのナンバの毛の抽出物は、 血糖降下作用を あるいは血糖値上昇抑制作用有し、 糖尿病の予防或いは治療に対して、 有効性で あることが明らかである。 産業上の利用分野  (3) From the above, it is clear that the extract of corn number hair has a hypoglycemic effect or an anti-hyperglycemic effect, and is effective for the prevention or treatment of diabetes. Industrial applications
本発明により、 トウモロコシのナン くの毛の抽出物の血糖値降下作用が明らか にされた。 該抽出物は、 糖尿病の予防 ·治療剤として、 或いは耐糖能障害に起因 する動脈硬化性血管障害に対する予防剤として用いることができる。 また、 該抽 出物を、 飲食品に含有せしめ、 これを摂取することにより、 日常の食生活のなか で、 継続的に糖尿病の改善或いは予防効果が期待できる。  INDUSTRIAL APPLICABILITY According to the present invention, the blood sugar lowering effect of an extract of corn hair was revealed. The extract can be used as a preventive or therapeutic agent for diabetes, or as a preventive agent for arteriosclerotic vascular disorders caused by impaired glucose tolerance. In addition, by incorporating the extract into foods and drinks and ingesting the extract, it is possible to expect continuous improvement or prevention of diabetes in daily eating habits.

Claims

請 求 の 範 囲 The scope of the claims
1 . トウモロコシのナンパの毛の抽出物を有効成分とする血糖値降下剤。 1. A hypoglycemic agent containing an extract of corn pick-up hair as an active ingredient.
2 . トウモロコシのナンパの毛が中国山東省産の品種掖単 1 2号または掖単 1 4 号トウモロコシ由来である請求項 1に記載の血糖値降下剤。  2. The blood sugar lowering agent according to claim 1, wherein the hair of the corn pick-up is derived from maize cultivar yemono No. 12 or yemono no. 14 from Shandong Province, China.
3 . トウモロコシのナンパの毛の抽出物を含有する血糖値降下作用又は血糖値上 昇抑制作用を有する飲食品。  3. A food or beverage containing an extract of corn pick-up hair and having a blood sugar lowering action or a blood sugar rise suppressing action.
4 . トウモロコシのナンパの毛が中国山東省産の品種掖単 1 2号または掖単 1 4 号トウモロコシ由来である請求項 3に記載の飲食品。  4. The food or drink product according to claim 3, wherein the corn wool hair is derived from maize cultivar ye simple no. 12 or ye simple no. 14 from Shandong Province, China.
5 . 血糖値降下作用又は血糖値上昇抑制作用を有する飲食品の製造のためのトゥ モロコシのナンバの毛の抽出物の使用。  5. Use of a hair extract of corn sorghum for the manufacture of a food or drink having a blood sugar lowering action or a blood sugar rise suppressing action.
6 . トウモロコシのナンパの毛が中国山東省産の品種掖単 1 2号または掖単 1 4 号トウモロコシ由来である請求項 5に記載の使用。  6. The use according to claim 5, wherein the hair of the corn pick-up is derived from maize cultivar yemono no. 12 or yemono no. 14 from Shandong Province, China.
7 . トウモロコシのナンパの毛の抽出物を投与することを特徴とする糖尿病の処 置方法。  7. A method for treating diabetes, which comprises administering an extract of corn pick-up hair.
8 . トウモロコシのナンバの毛が中国山東省産の品種掖単 1 2号または被単 1 4 号トウモロコシ由来である請求項 7に記載の処置方法。  8. The treatment method according to claim 7, wherein the corn number hair is derived from maize cultivar No. 12 or No. 14 from Shandong Province, China.
PCT/JP1999/002031 1998-04-17 1999-04-16 Hypoglycemic agents WO1999053936A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU33444/99A AU3344499A (en) 1998-04-17 1999-04-16 Hypoglycemic agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP10/107509 1998-04-17
JP10750998 1998-04-17
JP10/110679 1998-04-21
JP11067998 1998-04-21

Publications (1)

Publication Number Publication Date
WO1999053936A1 true WO1999053936A1 (en) 1999-10-28

Family

ID=26447535

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1999/002031 WO1999053936A1 (en) 1998-04-17 1999-04-16 Hypoglycemic agents

Country Status (4)

Country Link
KR (1) KR100601191B1 (en)
CN (1) CN1297353A (en)
AU (1) AU3344499A (en)
WO (1) WO1999053936A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002114701A (en) * 2000-10-05 2002-04-16 Meiji Milk Prod Co Ltd Composition for improving lipid metabolism
WO2006104350A1 (en) * 2005-03-30 2006-10-05 Endorphin F & B Inc. Manufacturing method of a drink containing corn silk extracts
JP2011140512A (en) * 2011-03-30 2011-07-21 Meiji Co Ltd Lipid metabolism-improving composition
JP2015101586A (en) * 2013-11-25 2015-06-04 カトリック ユニバーシティ インダストリー アカデミック コーオペレイション ファウンデーション Pharmaceutical composition for obesity prevention and treatment comprising maysin

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030083416A (en) * 2002-04-22 2003-10-30 변현규 It is
CN100400081C (en) * 2004-11-02 2008-07-09 华启洪 Medicine for treating diabetes and production method thereof
CN101254011B (en) * 2008-04-08 2012-01-11 吉林大学 Corn capillament drink and method of preparing the same
KR102281950B1 (en) * 2018-07-04 2021-07-26 한국식품연구원 Composition for reducing toxicity containing corn silk extract

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KOJIMA Y, ET AL.: "INTERFERON-INDUCING, ANTITUMOR, AND IMMUNOMODULATING ACTIVITIES OF A POLYSACCHARIDE FRACTION SEPARATED FROM CORN SILK", JOURNAL OF INTERFERON RESEARCH, MARY ANN LIEBERT, INC., NEW YORK, NY, US, vol. 13, no. SUPPL. 01, 1 January 1993 (1993-01-01), US, pages S128, XP002921220, ISSN: 0197-8357 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002114701A (en) * 2000-10-05 2002-04-16 Meiji Milk Prod Co Ltd Composition for improving lipid metabolism
JP4743947B2 (en) * 2000-10-05 2011-08-10 株式会社明治 Lipid metabolism improving composition
WO2006104350A1 (en) * 2005-03-30 2006-10-05 Endorphin F & B Inc. Manufacturing method of a drink containing corn silk extracts
JP2011140512A (en) * 2011-03-30 2011-07-21 Meiji Co Ltd Lipid metabolism-improving composition
JP2015101586A (en) * 2013-11-25 2015-06-04 カトリック ユニバーシティ インダストリー アカデミック コーオペレイション ファウンデーション Pharmaceutical composition for obesity prevention and treatment comprising maysin

Also Published As

Publication number Publication date
CN1297353A (en) 2001-05-30
AU3344499A (en) 1999-11-08
KR100601191B1 (en) 2006-07-13
KR20010074477A (en) 2001-08-04

Similar Documents

Publication Publication Date Title
AU2013308395C1 (en) Extraction method
US20030161903A1 (en) Carbohydrate Aborption Inhibitor and Method for Manufacturing the Same
JP5109117B2 (en) Sudachi-derived composition, and pharmaceutical composition, health food and drink and supplement containing the composition
EP2397039A1 (en) Compositions for delaying progression of diabetes using Salacia oblonga extract
JPH08225453A (en) Lipoprotein (a) depressor, cholesterol depressor and medicine containing the same
JPH038188B2 (en)
JP2001178429A (en) Functional antidiabetic drink
US11044930B2 (en) Composition comprising cinnamon extract
WO1999053936A1 (en) Hypoglycemic agents
AU710108B2 (en) Medicinal composition for diabetes
WO2005002602A2 (en) Composition for treating and/or preventing dysfunctions associated with type 2 diabetes mellitus and insulin resistance
US10561700B2 (en) Use of overground part of Hedychium coronarium Koenig in reducing blood glucose; extracts and compositions of overground part of Hedychium coronarium Koenig and their uses
WO2007100103A1 (en) Ameliorating agent for metabolic syndrome
JP2000342228A (en) Formulated tea of smallanthus sonchifol with mulberry leaf
JP2007008883A (en) Composition having blood glucose level-lowering action
EP2353605A1 (en) Use of overground part of hedychium coronarium koenig in reducing blood glucose; extracts and compositions of overground part of hedychium coronarium koenig and their uses
JP3476835B2 (en) Yacon / oolong blended food
CN110404029B (en) Composition with blood sugar reducing effect and preparation method and application thereof
JP5019708B2 (en) Composition for the treatment and prevention of diabetes
JP4524018B2 (en) Pharmaceutical composition and health food for prevention and treatment of non-insulin dependent diabetes mellitus comprising mulberry leaf and agaricus extract mixture
KR20040014534A (en) Oral composition comprising an extract from the bark of albizzia myriophylla
CN107029092A (en) A kind of mare's milk sugar-reduction traditional Chinese medicine composition and its preparation method and application
KR100473529B1 (en) Composition comprising an extract of sungisan crude drug complex as an effective ingredient for preventing and treating diabetes
JP2002212085A (en) Uric acid value-reducing agent
US20020172730A1 (en) Orals dosage noni formulations

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99805141.1

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1020007011210

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 09673453

Country of ref document: US

122 Ep: pct application non-entry in european phase
WWP Wipo information: published in national office

Ref document number: 1020007011210

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1020007011210

Country of ref document: KR